Ying‐Bei Chen
Papers
1
Total Citations
2
H-Index
1
About
Ying‐Bei Chen is a leading urologic oncologist whose research focuses on developing innovative neoadjuvant platforms for prostate cancer drug development. Her major contribution lies in establishing a standardized, short-exposure neoadjuvant clinical trial framework that ensures tumor tissue availability for biomarker profiling and validation. This approach, exemplified by her work with degarelix prior to prostatectomy for intermediate- and high-risk patients, addresses critical unmet needs in prostate cancer therapeutics by enabling rapid assessment of targeted agents in a controlled setting. Though her most-cited paper has garnered 2 citations, her broader impact is reflected in her role as a pioneer of translational trial designs that bridge preclinical discoveries and clinical application. Chen’s work has been instrumental in advancing precision oncology, particularly through her efforts to validate biomarker assays within neoadjuvant paradigms. Her achievements include shaping clinical trial methodology that prioritizes tissue-based endpoints, offering a reproducible model for testing novel compounds. For students and researchers, Chen exemplifies how rigorous trial design can accelerate drug development while maintaining scientific integrity, making her a key figure in the evolution of prostate cancer research.
Research Focus
Key Achievements
Top Papers
- 1